Login
Septerna, Inc. logo

Septerna, Inc.

septerna.com

What Do They Do?

Develops oral small-molecule drugs targeting GPCRs for patients with endocrine, immune and inflammatory, and metabolic diseases.

How Do They Make Money?

Revenue comes from research services and licenses under collaborations: partners fund research and development work, may pay upfront and milestone amounts, and may owe royalties on approved drug sales. The company has not generated revenue from product sales.

FY2025 revenue

Who Are Their Customers?

Pharmaceutical partners buy licenses and research and development services through collaboration agreements; Novo funds research work, and Vertex is also a customer.

Do Revenues Turn Into Profits?

Not on paper. It lost $48.9M in FY2025, but brought in more cash than it spent: $109.7M of free cash flow.

Operating income, FY2025
−149% of revenue
▲ +15% (Loss) vs FY2024 (−$80.8M, −7518%)
Net income, FY2025
−106% of revenue
▲ +32% (Loss) vs FY2024 (−$71.8M, −6679%)
Free cash flow, FY2025
239% of revenue
▲ Turned profitable vs FY2024 (−$69.6M, −6472%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ Turned to a loss
vs $8.2M in Q3 FY2025
  • Nov 4, 2026 Septerna selected SEP-204 as a development candidate The oral candidate is being developed for Graves’ disease and thyroid eye disease; Phase 1 trial initiation is planned for the first quarter of 2027.
  • Apr 13, 2026 Septerna began a Phase 1 trial of SEP-479 The oral PTH1R agonist is being tested in healthy volunteers for hypoparathyroidism.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support